Tongxinluo Treatment for Acute Myocardial Infarction has Important Academic Significance and Clinical Value
Dec 07,2023 | YILING
On November 16th, the results of the National Key R&D Program "Research on Intervention of Cardiovascular Event Chain by the Vein Theory and Health Theory Guidance System" were released in Beijing. Professor Yang Yuejin from Fuwai Hospital of the Chinese Academy of Medical Sciences has announced his latest research findings - the "CTS-AMI Study on Myocardial Protection in the Treatment of Acute Myocardial Infarction with Zhongguo Tongxinluo". The results showed that Tongxinluo Capsule can improve the 30 day and 1-year clinical outcomes of patients with ST segment elevation myocardial infarction (STEMI), especially in reducing cardiovascular mortality and serious complications, providing effective therapeutic drugs for improving the long-term prognosis of acute myocardial infarction.
The top international medical journal JAMA has published original research results from China, stating that Tongxinluo can reduce the risk of acute myocardial infarction death by 30%
Professor Yang Yuejin presented his research findings at the meeting
At the meeting, Professor Yang Yuejin from Fuwai Hospital of the Chinese Academy of Medical Sciences released the research results on myocardial protection in the treatment of acute myocardial infarction with Tongxinluo. Yang Yuejin introduced that this study is a sub project of the National Key R&D Program "Research on Intervention of Cardiovascular Event Chain by the Vein Theory Health Theory Guidance System". A total of 3797 patients with ST segment elevation myocardial infarction (STEMI) within 24 hours of onset from 124 hospitals in China were included in a randomized, double-blind, multicenter, placebo-controlled clinical trial. The results showed that Tongxinluo significantly reduced the risk of major adverse cardiovascular and cerebrovascular events (including cardiogenic death, recurrent myocardial infarction, emergency coronary revascularization, and stroke) by 36% and reduced the risk of cardiogenic death by 30%; The study aimed to continuously reduce the risk of adverse cardiovascular and cerebrovascular events by 36% and cardiogenic death by 27% through the use of Tongxinluo over the course of one year, providing effective therapeutic drug options for improving the long-term prognosis of acute myocardial infarction.
The research paper "Clinical efficacy of Zhongguo Tongxinluo in the treatment of acute myocardial infarction - CTS-AMI randomized clinical study" was recently published in the Journal of the American Medical Association (JAMA). JAMA, with an impact factor of 120.7 points, is a comprehensive clinical medicine journal sponsored by the American Medical Association. It was founded in 1883 and is one of the world's top four medical journals along with the New England Journal of Medicine, The Lancet, and the British Medical Journal.
Research to Promote the Modernization and Internationalization of Traditional Chinese Medicine and Take Solid Steps
Academician Gao Runlin delivers a speech
Professor Gao Runlin, an academician of the CAE Member and professor of Fuwai Hospital of the Chinese Academy of Medical Sciences, said in his speech that the significance of the study is not only to add solid evidence-based medical evidence for Tongxinluo, but also to set a model for the integration of traditional Chinese medicine and western medicine and the study of traditional Chinese medicine and traditional Chinese medicine with modern scientific methods. Explored a path for traditional Chinese medicine to enter the world and set a model.
cademician Zhang Boli delivers a speech
In his speech, Professor Zhang Boli, an academician of the CAE Member, a master of traditional Chinese medicine and a professor of Tianjin University of Traditional Chinese Medicine, said that this research is a major breakthrough in the field of cardiovascular science, the integration of traditional Chinese and western medicine, and an important achievement of evidence-based medicine. It will provide ideas and methods for clinical use of traditional Chinese medicine, and also play an important role in evidence-based research on clinical evaluation of traditional Chinese medicine, with important academic significance and clinical value. I hope the team can summarize their experience and promote it nationwide, so that more clinical research on traditional Chinese medicine can reach this level.
In her speech, Professor Han Yaling, an academician of the CAE Member and the General Hospital of the Northern Warfare Zone, mentioned that the release of the research results not only demonstrated the strength of Chinese researchers, but also found a suitable combination point for the treatment of major clinical diseases with integrated traditional and western medicine, which opened a new way to bring thousands of years of cultural treasures of traditional Chinese medicine to the world.
Shen Jianzhong, Deputy Director of China Biotechnology Development Center, delivered a speech
Shen Jianzhong, Deputy Director of the China Biotechnology Development Center, stated in his speech that the inclusion of randomized controlled clinical trials of traditional Chinese medicine in one of the four major international medical journals is of great significance and also a major breakthrough in evidence-based medicine research of traditional Chinese medicine, taking a solid step towards the internationalization of traditional Chinese medicine.
Professor Eric Peterson from the University of Texas in the United States provides comments on this research achievement
Research participant Professor Eric Peterson from the University of Texas Southwestern Medical Center in the United States stated that this is a very high-quality randomized, double-blind, controlled clinical trial. As Richard Bach of the University of Washington School of Medicine pointed out in Editor's Note, if we can determine what its truly active active ingredients are, it will have significant implications and impact on the treatment of acute myocardial infarction patients worldwide.
At the 20th World Congress of Traditional Chinese Medicine and the 5th Member Representative Conference of the World Federation of Chinese Medicine, as well as the 20th anniversary commemoration conference of the establishment of the World Federation of Chinese Medicine, held in Manila, Philippines, the research results of "Zhongguo Tongxinluo Treatment for Acute Myocardial Infarction and Myocardial Protection Research" were simultaneously released.